NEW YORK, April 14 (GenomeWeb News) - Galapagos has signed a two-year, €1.3 million ($1.7 million) agreement with Cystic Fibrosis Foundation Therapeutics, the drug discovery and development affiliate of the Cystic Fibrosis Foundation, the company said yesterday.
Galadeno, Galapagos' Leiden, Netherlands-based services unit, will apply the company's siRNA and cDNA collections to discover and validate novel drug targets for potential new cystic fibrosis therapies. Galapagos will have the option to further develop targets, the company said.